Renke Biotech develops a proprietary cfDNA chromatin open region detection technology for early cancer screening, utilizing a comprehensive cancer chromatin database to enhance sensitivity and specificity. This approach enables accurate detection of tumor markers from blood samples, addressing the challenges of early cancer diagnosis and the complexities of traditional pathological testing.
Funding
Funding not disclosed
Founders
Product
Problem
Early cancer screening faces challenges in accurately detecting tumor markers from blood samples, while traditional pathological testing can be complex and invasive. Current methods may lack the sensitivity and specificity needed for reliable early cancer diagnosis across a wide range of cancer types.
Solution
Renke Biotech has developed a cfDNA chromatin open region detection technology for early cancer screening. This technology utilizes a comprehensive cancer chromatin database to enhance the detection of tumor markers in blood samples. By focusing on chromatin open regions, the approach aims to improve both the sensitivity and specificity of early cancer detection, enabling accurate identification of the primary tumor site. The technology offers a less invasive and more convenient alternative to traditional pathological testing.
Target Audience
The primary target audience includes healthcare providers, hospitals, and individuals seeking early and accurate cancer screening solutions.
Features
- Proprietary cfDNA chromatin open region detection technology
- Comprehensive cancer chromatin database for enhanced sensitivity and specificity
- Non-invasive blood-based test for early cancer screening
- Accurate identification of the primary tumor site
- Applicable to a wide range of cancer types
- AI-driven analysis of biomarkers for correlation with cancer type and treatment options